Anticoagulation in Patients with Atrial High-rate Episodes Detected by Cardiac Implantable Electronic Devices-Reference-Cited by-同舟云学术

Anticoagulation in Patients with Atrial High-rate Episodes Detected by Cardiac Implantable Electronic Devices

Published:2024-02 Issue:7 Volume:30 Page:485-488
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Spartalis Michael¹,Kontogiannis Christos²,Spartalis Eleftherios³,Iliopoulos Dimitrios C.³,Siasos Gerasimos⁴

Affiliation:

1. 3rd Department of Cardiology, Sotiria Thoracic Diseases General Hospital, National and Kapodistrian University of Athens, Athens, Greece

2. Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece

3. Laboratory of Experimental Surgery and Surgical Research ‘N.S. Christeas’, Medical School, National and Kapodistrian University of Athens, Athens, Greece

4. 3 rd Department of Cardiology, Sotiria Thoracic Diseases General Hospital, National and Kapodistrian University of Athens, Athens, Greece

Abstract

Abstract: Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias that are identified by the use of continuous rhythm monitoring devices such as pacemakers, defibrillators, or implantable cardiac monitors. Nevertheless, the therapeutic implications of these rhythm disturbances remain uncertain. The presence of AHRE is associated with an increased risk of stroke as compared to patients who do not exhibit AHRE. The utilisation of oral anticoagulation has the ability to mitigate the likelihood of stroke occurrence in patients with AHRE. However, it is important to note that this treatment approach is also linked to a severe bleeding rate of approximately 2% per year. The stroke rate among individuals diagnosed with AHRE appears to be comparatively lower when compared to patients diagnosed with atrial fibrillation. The efficacy and safety of anticoagulation in patients with AHRE have yet to be definitively established. Further research is required to provide a comprehensive understanding of the effectiveness and safety of oral anticoagulation in individuals with AHRE.

Publisher

Bentham Science Publishers Ltd.

Reference28 articles.

1. Freedman B.; Boriani G.; Glotzer T.V.; Healey J.S.; Kirchhof P.; Potpara T.S.; Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017,14(12),701-714

2. Lip G.Y.H.; Proietti M.; Potpara T.; Mansour M.; Savelieva I.; Tse H.F.; Goette A.; Camm A.J.; Blomstrom-Lundqvist C.; Gupta D.; Boriani G.; Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace 2023,25(9),euad226

3. Miyazawa K.; Pastori D.; Martin D.T.; Choucair W.K.; Halperin J.L.; Lip G.Y.H.; Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. Europace 2022,24(3),375-383

4. Hindricks G.; Potpara T.; Dagres N.; Arbelo E.; Bax J.J.; Blomström-Lundqvist C.; Boriani G.; Castella M.; Dan G.A.; Dilaveris P.E.; Fauchier L.; Filippatos G.; Kalman J.M.; La Meir M.; Lane D.A.; Lebeau J.P.; Lettino M.; Lip G.Y.H.; Pinto F.J.; Thomas G.N.; Valgimigli M.; Van Gelder I.C.; Van Putte B.P.; Watkins C.L.; Kirchhof P.; Kühne M.; Aboyans V.; Ahlsson A.; Balsam P.; Bauersachs J.; Benussi S.; Brandes A.; Braunschweig F.; Camm A.J.; Capodanno D.; Casadei B.; Conen D.; Crijns H.J.G.M.; Delgado V.; Dobrev D.; Drexel H.; Eckardt L.; Fitzsimons D.; Folliguet T.; Gale C.P.; Gorenek B.; Haeusler K.G.; Heidbuchel H.; Iung B.; Katus H.A.; Kotecha D.; Landmesser U.; Leclercq C.; Lewis B.S.; Mascherbauer J.; Merino J.L.; Merkely B.; Mont L.; Mueller C.; Nagy K.V.; Oldgren J.; Pavlović N.; Pedretti R.F.E.; Petersen S.E.; Piccini J.P.; Popescu B.A.; Pürerfellner H.; Richter D.J.; Roffi M.; Rubboli A.; Scherr D.; Schnabel R.B.; Simpson I.A.; Shlyakhto E.; Sinner M.F.; Steffel J.; Sousa-Uva M.; Suwalski P.; Svetlosak M.; Touyz R.M.; Dagres N.; Arbelo E.; Bax J.J.; Blomström-Lundqvist C.; Boriani G.; Castella M.; Dan G-A.; Dilaveris P.E.; Fauchier L.; Filippatos G.; Kalman J.M.; La Meir M.; Lane D.A.; Lebeau J-P.; Lettino M.; Lip G.Y.H.; Pinto F.J.; Neil Thomas G.; Valgimigli M.; Van Gelder I.C.; Watkins C.L.; Delassi T.; Sisakian H.S.; Scherr D.; Chasnoits A.; Pauw M.D.; Smajić E.; Shalganov T.; Avraamides P.; Kautzner J.; Gerdes C.; Alaziz A.A.; Kampus P.; Raatikainen P.; Boveda S.; Papiashvili G.; Eckardt L.; Vassilikos V.; Csanádi Z.; Arnar D.O.; Galvin J.; Barsheshet A.; Caldarola P.; Rakisheva A.; Bytyçi I.; Kerimkulova A.; Kalejs O.; Njeim M.; Puodziukynas A.; Groben L.; Sammut M.A.; Grosu A.; Boskovic A.; Moustaghfir A.; Groot N.; Poposka L.; Anfinsen O-G.; Mitkowski P.P.; Cavaco D.M.; Siliste C.; Mikhaylov E.N.; Bertelli L.; Kojic D.; Hatala R.; Fras Z.; Arribas F.; Juhlin T.; Sticherling C.; Abid L.; Atar I.; Sychov O.; Bates M.G.D.; Zakirov N.U.; 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021,42(5),373-498

5. Proietti M.; Romiti G.F.; Vitolo M.; Borgi M.; Rocco A.D.; Farcomeni A.; Miyazawa K.; Healey J.S.; Lane D.A.; Boriani G.; Basili S.; Lip G.Y.H.; Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. Eur J Intern Med 2022,103,84-94